Auspex Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops medicines for hyperkinetic movement disorders and other rare diseases. The company specializes in applying deuterium chemistry to known molecules to create novel therapies. Its portfolio includes Austedo (SD-809), a solution for the potential treatment of chorea associated with Huntington's disease, tardive dyskinesia, and Tourette syndrome; SD-560, a solution for fibrotic conditions; and SD-1077, a solution for Parkinson's disease. The company was founded in 2001 and is headquartered in San Diego, California. As of May 5, 2015, Auspex Pharmaceuticals, Inc. operates as a subsidiary of Teva Pharmaceutical Industries Limited.